May 15, 2023

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

Brad Sorensen
312-265-9574
bsorensen@zacks.com

scr.zacks.com

10 S. Riverside Plaza, Chicago, IL 60606

Ensysce Biosciences (ENSC-NASDAQ)

ENSC: Opioid Overdose Protection Data is a Game-Changing Development

ENSC is a clinical stage pharmaceutical company dedicated to bringing a novel opioid to the market that resists the addictive properties that have plagued society.

Current Price (05/12/23)	$3.15
Valuation	**$17.85**

OUTLOOK

Ensysce Biosciences is committed to finding a solution to the opioid crisis plaguing the US and other developed countries around the world. Through its proprietary TAAP technology Ensysce is in the process of receiving approval for an abuse-resistant yet still pain-relieving opioid.

The company released results from testing of its PF614-MPAR drug, which proved it can limit opioid exposure when too many pills are swallowed. We believe this is an important development in the fight against opioid addiction and a catalyst for the stock.

SUMMARY DATA

52-Week High	**$208.50**
52-Week Low	**$3.39**
One-Year Return (%)	**-98.07**
Beta	**0.58**
Average Daily Volume (sh)	**321,568**
Shares Outstanding (mil)	**2**
Market Capitalization ($mil)	**$4**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**N/A**
Insider Ownership (%)	**53**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2023 Estimate	**N/A**
P/E using 2024 Estimate	**N/A**
Zacks Rank	**N/A**

Risk Level	**High**
Type of Stock	**Small-Blend**
Industry	**Med-Biomed/Gene**

ZACKS ESTIMATES

Revenue
(in millions of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2021	N/A	N/A	1.2A	0.4E	1.7A
2022	0.6A	0.2A	0.3A	1.4A	2.5A
2023	0.6E	0.7E	0.8E	0.8E	2.9E
2024	0.5E	0.5E	0.6E	0.6E	2.2E

Earnings per share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2021	N/A	-0.39A	-0.71A	0.45A	-1.48A
2022	-0.06A	-0.24A	-5.13A	-2.55A	11.62A*
2023	-3.55E	-3.60E	-3.62E	-3.66E	-14.43E
2024	-5.10E	-5.11E	-5.14E	-5.19E	-20.54E

*quarters don't add to yearly total in 2022 due to reverse stock split and share issuance.

© Copyright 2023, Zacks Investment Research. All Rights Reserved.

Company Update

Enscyse Biosciences has been one of the companies that we cover that we believe most of America is hoping is successful. The opioid crisis remains a plague on the American public and is destroying families and whole communities. The National Institute on Drug Abuse reported more than 106,000 overdose deaths in 2021—and that doesn't count the millions of family members and friends impacted by those deaths. Enscyse has extremely promising technology that aims to eliminate the ability to overdose or abuse the pain reliever, while still providing the much-needed pain relief that many Americans need.

We are extremely excited about today's announcement that the company has completed the final Part B part of a study designed to test the effectiveness of PF614-MPAR, which is the company's pain medication with overdose protection. The exciting part is that the results of this trial were successful—great news for the company and potentially a game-changing development in the fight against opioid addiction. The company released the following statement regarding the results of the test:

- "We believe PF614-MPAR is the first drug which can limit opioid exposure when too many pills are swallowed, protecting against overdose. In our PF614-MPAR-101 study, the data showed that a 25 mg dose of PF614-MPAR, delivered oxycodone as designed for what may be a prescribed dose of one to two capsules. Importantly, when administering three or more capsules simultaneously, the amount of opioid released and absorbed into the circulation diminished as compared to the unprotected PF614, thereby substantially reducing the risk of overdose."

Overdosing on opioids is a plague on society and destroying families and lives. Having the possibility of a drug that can provide the needed pain relief, while greatly reducing the risk of overdosing is, in our view, an extremely exciting development. The company will now work to define the drug for all planned dosage strengths in order to optimize effects across various dose ranges.

The company also announced an offering of 1.8 million shares of common stock along with Series A-1 and A-2 warrants to purchase the equivalent number of shares. This offering should provide Ensysce with the cash (approximately $7 million before fees) it needs to continue this exciting mission to bring this vital product to market. However, as a result of the offering, we are reducing our price target in proportion to the dilution that will occur once the shares are offered. We are also reducing the discount rate due to our belief that the risks have decreased modestly after the positive trial. The result is a new price target of $17.85, which we continue to believe is a relatively conservative price target given the potential of the solutions ENSC is developing.

The market for biotechnology stocks has been bumpy lately but we strongly believe, and have shown above, the technology being advanced by Ensysce has enormously important potential for the American public—and for investors with a higher tolerance for risk and volatility in the near term, ENSC is a stock worth looking at.

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Brad Sorensen, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.